دورية أكاديمية

Efficacy and safety of adding sotagliflozin, a dual sodium‐glucose co‐transporter ( SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m 2

التفاصيل البيبلوغرافية
العنوان: Efficacy and safety of adding sotagliflozin, a dual sodium‐glucose co‐transporter ( SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m 2
المؤلفون: Danne, Thomas, Edelman, Steven, Frias, Juan Pablo, Ampudia‐Blasco, Francisco Javier, Banks, Philip, Jiang, Wenjun, Davies, Michael J., Sawhney, Sangeeta
المصدر: Diabetes, Obesity and Metabolism ; volume 23, issue 3, page 854-860 ; ISSN 1462-8902 1463-1326
بيانات النشر: Wiley
سنة النشر: 2020
المجموعة: Wiley Online Library (Open Access Articles via Crossref)
الوصف: Sotagliflozin, a dual sodium‐glucose co‐transporter (SGLT)1/SGLT2 inhibitor, is currently approved in Europe as an adjunct to optimal insulin therapy in adults with type 1 diabetes (T1D) and a body mass index (BMI) ≥ 27 kg/m 2 . In this post hoc analysis, efficacy at 24 weeks and safety at 52 weeks from pooled phase 3 clinical trials were evaluated in patients with baseline BMI ≥ 27 kg/m 2 . Sotagliflozin 200 mg and 400 mg added to insulin reduced glycated haemoglobin level and increased time in range assessed by continuous glucose monitoring versus placebo and also reduced body weight and systolic blood pressure. Differences in efficacy endpoints between sotagliflozin and placebo tended to be greater among patients with BMI ≥ 27 kg/m 2 compared to those with baseline BMI < 27 kg/m 2 . Consistent with published results for the entire population, fewer severe hypoglycaemia and documented hypoglycaemia ≤3.1 mmol/L events and a higher incidence of diabetic ketoacidosis occurred with sotagliflozin versus placebo in patients with BMI ≥ 27 kg/m 2 . Sotagliflozin as an adjunct to optimized insulin therapy in overweight/obese patients with T1D addressed some unmet needs and may help achieve optimal glycaemic control, mitigating weight gain without increasing hypoglycaemia risk in this high‐risk population.
نوع الوثيقة: article in journal/newspaper
اللغة: English
DOI: 10.1111/dom.14271
الإتاحة: https://doi.org/10.1111/dom.14271Test
حقوق: http://onlinelibrary.wiley.com/termsAndConditions#vorTest
رقم الانضمام: edsbas.662B1A82
قاعدة البيانات: BASE